Peitho trial pe
WebPEITHO-2 is a prospective, multicenter, phase IV, single-armed (management) trial that has been designed to address clinically relevant unresolved issues in the management of … WebHI-PEITHO is the largest, most rigorous trial in the PE space intended to address critical gaps in PE clinical evidence. This trial reflects Boston Scientific’s investment and commitment to providing the highest level of scientific evidence to ultimately help guide clinical practice. -Dr. Michael R. Jaff, BSC Ekos™ Endovascular System
Peitho trial pe
Did you know?
WebThe HI-PEITHO trial will include up to 65 sites across the United States and Europe. Target enrollment is 406 to 544 patients, which is based on a statistically robust adaptive trial design including a prespecified planned interim analysis. The trial will follow all rules of clinical research as set forth in the Declaration of Helsinki. Figure 1. Webthe recent Pulmonary Embolism Thrombolysis (PEITHO) trial. 3 Several meta-analyses have disputed the use of echocar-diogram and cardiac biomarkers for risk stratifi cation of normotensive patients. A 2004 meta-analysis of echocar-diography in normotensive patients found the positive predictive value for PE-related in-hospital mortality to
WebApr 27, 2024 · The PEITHO (Pulmonary Embolism Thrombolysis) trial was a randomized (1:1) comparison of th rombolysis with tenecteplase versus placebo in normotensive patients with acute PE, right ventricular (RV) dysfunction on imaging, and a positive cardiac troponin test result. Both treatment arms received standard anticoagulation. WebMay 15, 2024 · PEITHO was a multicenter, double-blind, placebo-controlled randomized trial Outcomes: Long-term mortality Clinical and Echocardiographic parameters Inclusion: ≥18 years of age Confirmed acute PE with first symptoms ≤15d RV dysfunction (Diagnosed by echocardiography or computed tomography) Myocardial injury (Diagnosed by positive …
WebBackgroundThe European Society of Cardiology guidelines for the diagnosis and management of acute pulmonary embolism (PE) developed in collaboration with the European Respiratory Society (ERS) has been updated in … WebApr 10, 2014 · Background: The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. Methods: In a randomized, double-blind trial, we …
WebHI-PEITHO is a multi-center, prospective, randomized, controlled trial in the U.S. and Europe that will compare the outcomes of ultrasound-facilitated, catheter-directed, thrombolysis …
WebJun 8, 2024 · The 2014 Pulmonary Embolism Thrombolysis (PEITHO) trial randomized 1,005 patients with a submassive PE (hemodynamic stability with RV strain and elevated … capdカテーテルWebNov 4, 2015 · Participation in another clinical trial during the present clinical trial or within the last three months ... Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematol. 2024 Sep;8(9):e627-e636. doi: 10.1016/S2352-3026(21 ... cape117 コードWebThe Pulmonary Embolism Thrombolysis (PEITHO) trial evaluated a single-dose tenecteplase with heparin therapy for the treatment of “intermediate risk” acute pulmonary embolism. … cape bev 投与スケジュールWebJul 20, 2024 · Background. There is scant evidence published on the long-term outcomes of systemic thrombolysis in acute submassive PE. Many advocate for the use of systemic … cape2003 インストールWebJan 1, 2013 · Description: The goal of the trial was to evaluate fibrinolysis compared with placebo among normotensive patients with acute intermediate-risk pulmonary embolism. … cape2003 マニュアルWebJul 20, 2024 · The PEITHO study was a randomized, multi-national, double-blind, placebo-controlled trial Primary Results Long-term outcomes available for > 98% of patients Median follow up 37.8 months Critical Findings: Overall mortality At < 30 days No statistically significant difference Tenecteplase 2.2% vs. Placebo 2.9% (p = 0.595) capdとは ビジネスWebEarly switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial Lancet Haematol. 2024 Sep;8 ... This trial is registered with the EU Clinical Trials Register (EudraCT 2015-001830-12) and ClinicalTrials.gov (NCT02596555). capdとは 看護